Conditions: Pulmonary Hypertension
Keywords: pulmonary hypertension bosentan BENEFIT CTEPH inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 151
Healthy volunteers: no

Brief summary:
The present trial investigates the long-term safety, tolerability and efficacy of bosentan in patients with inoperable CTEPH.

Detailed description:

Arms:
arm 1: Open label bosentan treatment

Interventions: intervention 1: bosentan
Intervention descriptions: intervention 1: Oral bosentan

* Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients
* Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight \< 40 kg)

Protocol document: